Influence of acute viral hepatitis on phenytoin kinetics and protein binding

Patients with liver disease are thought to have abnormal responses to drugs metabolized by the liver. although supportive evidence is sparse. The influence of acute viral hepatitis on the pharmacokinetics and protein binding of phenytoin (DPH) was examined in 5 patients. A longitudinal study design was used so that each patient acted as his own control. DPH clearance was unaffected by acute viral hepatitis over the concentration range studied. but the percentage of un bound DPH increased by an average of nearly one‐third during acute viral hepatitis. A small decline in serum albumin concentration and elevated serum bilirubin levels may be responsible for the alterations in protein binding. These results indicate that acute inflammatory liver disease has complex and perhaps paradoxical effects on drug disposition. Clinical and laboratory observations including plasma drug concentrations. still provide the best means for adjusting dosage regimens in patients with fluctuating hepatic function.

[1]  A. Breckenridge.  Pathophysiological factors influencing drug kinetics. , 2009, Acta pharmacologica et toxicologica.

[2]  M. Eadie,et al.  Plasma protein binding of diphenylhydantoin Effects of sex hormones, renal and hepatic disease , 1974, Clinical pharmacology and therapeutics.

[3]  L. Ranek,et al.  Plasma half‐life of phenylbutazone in patients with impaired liver function , 1974, Clinical pharmacology and therapeutics.

[4]  Diphenylhydantoin side effects and serum albumin levels , 1973, Clinical pharmacology and therapeutics.

[5]  M. Eadie,et al.  Plasma levels of anticonvulsants. , 1973, Australian and New Zealand journal of medicine.

[6]  Safe prescribing in liver disease. , 1973, British medical journal.

[7]  W. Steinbrunn,et al.  Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. , 1973, Annals of internal medicine.

[8]  N. Gerber,et al.  Acute intoxication with 5,5-diphenylhydantoin (Dilantin) associated with impairment of biotransformation. Plasma levels and urinary metabolites; and studies in healthy volunteers. , 1972, Annals of internal medicine.

[9]  J. Koch-weser.  Drug therapy. Serum drug concentrations as therapeutic guides. , 1972, The New England journal of medicine.

[10]  S. Curry,et al.  Plasma disappearance and cerebral effects of chlorpromazine in cirrhosis. , 1972, Clinical science.

[11]  Joseph M. Garfield,et al.  Clinical Pharmacology: Basic Principles in Therapeutics , 1972 .

[12]  J. Wagner,et al.  Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation. , 1972, Research communications in chemical pathology and pharmacology.

[13]  C. E. Becker,et al.  Altered protein binding of diphenylhydamtoin in uremic plasma. , 1972, The New England journal of medicine.

[14]  A. Glazko,et al.  Diphenylhydantoin metabolism in uremia. , 1971, The New England journal of medicine.

[15]  C. Bahr,et al.  Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function. , 1971, The New England journal of medicine.

[16]  A. Rane,et al.  PLASMA PROTEIN BINDING, PLASMA CONCENTRATIONS, AND EFFECTS OF DIPHENYLHYDANTOIN IN MAN * , 1971, Annals of the New York Academy of Sciences.

[17]  H. Kutt,et al.  BIOCHEMICAL AND GENETIC FACTORS REGULATING DILANTIN METABOLISM IN MAN * , 1971, Annals of the New York Academy of Sciences.

[18]  A. Rane,et al.  Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinemic infants. , 1971, The Journal of pediatrics.

[19]  A. Rane,et al.  Plasma protein binding of diphenylhydantoin in man; Interaction with other drugs and the effect of temperature and plasma dilution , 1970, Clinical pharmacology and therapeutics.

[20]  H. Remmer,et al.  The role of the liver in drug metabolism , 1970 .

[21]  F. Sjöqvist,et al.  Abnormal pharmacokinetics of phenytoin in a patient with uraemia. , 1970, Lancet.

[22]  K. Arnold,et al.  The rate of decline of diphenylhydantoin in human plasma , 1970, Clinical pharmacology and therapeutics.

[23]  C. Kunin.  Drugs, receptors and serum protein binding. , 1969, The New England journal of medicine.

[24]  A. Glazko,et al.  Metabolic disposition of diphenylhydantoin in normal human subiects following intravenous administration , 1969, Clinical pharmacology and therapeutics.

[25]  S. Sherlock,et al.  Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy. , 1968, Lancet.

[26]  I. Z. Steinberg,et al.  Ultracentrifugation Studies with Absorption Optics. V. Analysis of Interacting Systems Involving Macromolecules and Small Molecules , 1966 .

[27]  H. Kutt,et al.  DIPHENYLHYDANTOIN AND PHENOBARBITAL TOXICITY. THE ROLE OF LIVER DISEASE. , 1964, Archives of neurology.

[28]  K. Tanaka.  [THE PHARMACOLOGY OF ANTICONVULSANTS]. , 1964, Nihon Ishikai zasshi. Journal of the Japan Medical Association.

[29]  G. Odell,et al.  The dissociation of bilirubin from albumin and its clinical implications. , 1959, The Journal of pediatrics.

[30]  S. Sherlock,et al.  Diseases of the Liver and Biliary System , 1955 .